CD40LG and hepatocellular carcinoma: As shown in Table 2, the results were as follows: 1.1% of patients with CHB were anti-HDV IgG positive; 3.3% of patients with LC were anti-HDV IgG positive, and 1.1% were anti-HDV IgM positive; 2.7% of patients with HCC were anti-HDV IgG positive, and 1.6% were anti-HDV IgM positive; and 7.1% of patients with LF were anti-HDV IgG positive, and 2.2% were anti-HDV IgM positive.